Harvard Bioscience (HBIO) Free Cash Flow (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Free Cash Flow data on file, last reported at -$1.1 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$1.1 million, down 144.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 273.78% YoY), and the FY2025 annual result was $5.5 million, up 554.4% from the prior year.
• Free Cash Flow slipped to -$1.1 million in Q1 2026 per HBIO's latest filing, from -$545000.0 in the prior quarter.
• Over five years, Free Cash Flow peaked at $4.1 million in Q3 2023 and troughed at -$2.5 million in Q1 2022.
• A 5-year average of $881235.3 and a median of $877000.0 in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow plunged 377.31% in 2022, then soared 1901.93% in 2023.
• A 5-year view of Free Cash Flow shows it stood at $2.4 million in 2022, then soared by 42.1% to $3.5 million in 2023, then tumbled by 59.0% to $1.4 million in 2024, then sank by 138.27% to -$545000.0 in 2025, then slumped by 99.63% to -$1.1 million in 2026.
• Business Quant data shows HBIO's Free Cash Flow at -$1.1 million in Q1 2026, -$545000.0 in Q4 2025, and $877000.0 in Q3 2025.